AB vs NVZMY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AB and NVZMY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AB and NVZMY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

AllianceBernstein is a global investment management firm that runs research-intensive active strategies across equities, fixed income, alternatives, and multi-asset portfolios. It serves three client channels: Institutional Services (pensions, endowments, insurers, and central banks), Retail Services (mutual funds and separately managed accounts), and Private Wealth Management for high-net-worth families. Assets under management reached about $905 billion by mid-2026, split fairly evenly across institutional, retail, and private-wealth clients, and the firm earns the bulk of its revenue from asset-based management fees plus performance fees and Bernstein Research services. Equitable Holdings (EQH) is the controlling owner, holding a large majority economic interest through the operating partnership.

Full AB guide

Novonesis (legally Novozymes A/S) makes enzymes, microbial cultures, probiotics, yeast and other biological ingredients that customers use to make products work better or with less chemistry, energy or waste. It reports two divisions. Food & Health Biosolutions (~45% of H1 2026 sales) covers Food & Beverages, such as dairy cultures, baking and brewing enzymes and plant-based solutions (EUR 748 million in H1 2026), and Human Health, including probiotics, human milk oligosaccharides (HMOs) for infant formula and protein solutions (EUR 251 million). Planetary Health Biosolutions (~55%) covers Household Care, mainly detergent enzymes (EUR 425 million), and Agriculture, Energy & Tech (EUR 811 million), which spans biofuel enzymes and yeast, feed additives, crop biologicals and industrial processing aids. Group sales were EUR 4.16 billion in 2025 and EUR 2.24 billion in the first half of 2026.

Full NVZMY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AB drivers: Assets under management scale; Distribution-driven income.
• NVZMY drivers: Food & Beverages momentum; Biofuels and the Energy business.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: AB's revenue is tightly linked to markets, so a downturn in equities or bonds would shrink the fee base and the distribution alongside it. For NVZMY, the first risk is valuation and expectations: Novonesis was worth about DKK 191 billion (~EUR 25.6 billion) at the end of 2025 against EUR 1.54 billion of 2025 adjusted EBITDA, so a slowdown from the 7% to 8% growth now guided could hurt the shares more than the business.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AB if you believe its drivers more; NVZMY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AB and NVZMY guides.

AB. AB trades at a modest earnings multiple (roughly 11x trailing) that reflects its status as a mature, market-sensitive asset manager rather than a growth stock. The standout feature is the high distribution yield near 9%, which is a function of the MLP pass-through structure that returns almost all cash to unitholders each quarter. Because the payout floats with adjusted profit, both the yield and the multiple should be read against the risk that markets or flows turn negative.

NVZMY. The trailing figures come from adding H1 2026 to full-year 2025 and removing H1 2025. Reported net profit is held down by purchase-price amortization from the Chr. Hansen merger and Feed Enzyme Alliance deal: adjusted net profit excluding that amortization was EUR 929 million in 2025 and EUR 507 million in H1 2026, against reported net profit of EUR 584 million and EUR 371 million. That is why diluted EPS was EUR 0.80 in H1 2026 while adjusted EPS excluding amortization was EUR 1.09. Free cash flow before acquisitions was EUR 770 million in 2025, about 19% of sales, but should be lower relative to sales while capex runs at 12% to 14%.

Headline figures (approximate, JULY 2026): AB shows assets under management ~$905B, revenue (ttm, gaap) ~$4.5B, q1 2026 adjusted epu ~$0.83, quarterly distribution ~$0.83/unit; NVZMY shows net sales (ttm to june 2026) ~EUR 4.30B, adjusted ebitda (ttm) ~EUR 1.60B (37.7% H1 2026 margin), net profit (ttm) ~EUR 632M, 2026 guidance 7% to 8% organic growth, margin at high end of 37% to 38%.

AB and NVZMY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AB and NVZMY exposure against your real portfolio. It is not an investment adviser.